Aquinox discards lead drug, chops half of its staff in wake of PhIII disaster
When Aquinox conceded utter failure on its Phase III trial two weeks ago, execs were clear that there was nothing left to salvage. They …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
